))
Bacteriophage Drug Development and Regulatory Affairs with Dr. Carrie-Lynn Langlais Furr, CEO and Co-founder at Bacteriophage & Drug Development Consultants (BDDC)
Manage episode 354040837 series 3287704
Sisällön tarjoaa Steven Yang. Steven Yang tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
As more phage-based and phage-derived products and therapies emerge, swift decisions and strategies in drug development, designing clinical trials and approaching regulatory agencies come in handy. In this week's Phage Therapy Today, we sit down with Dr. Carrie-Lynn Langlais Furr, coming from a solid bacteriophage science background and coming with more than a decade's experience in phage related drug development and regulatory affairs, to talk about her advise on how to navigate these waters. Let's give it a listen to what some potential challenges lay ahead of us and how to be better prepared.
Find out more about Dr. Furr and her company Bacteriophage & Drug Development Consultants (BDDC) @https://www.linkedin.com/in/bacteriophage-and-drug-development-consultants/
19 jaksoa
Jaa
